A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer

Hepato-Gastroenterology

Volumn 55, Issue 86-87, 2008, Pages 1631-1635

  Nakajima, Yasuaki ^a   Suzuki, Tomoyoshi ^a   Haruki, Shigeo ^a   Ogiya, Kazuo ^a   Kawada, Kenro ^a   Nishikage, Tetsuro ^a   Nagai, Kagami ^a   Kawano, Tatsuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Docetaxel; Esophageal squamous cell cancer; Nedaplatin; Second line chemotherapy

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NEDAPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PILOT PROJECTS; TAXOIDS;

EID: 57049166512     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Akiyama H, Tsurumaru M, Udagawa H, et al: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220:364-373.
2. Ando N, Ozawa S, Kitagawa Y, et al: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232:225-232.
3. Low S, Fok M, Chow S, et al: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus. J Thorac Cardiovasc Surg 1997; 114:210-217.
4. Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979-1984.
5. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727-1733.
6. Pouliquen X, Levard H, Hay JM, et al: 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg 1996; 223:127-133.
7. Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 2003; 21:4592-4596.
8. Muro K, Ando N, Nishimaki A: A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG9905). Proc ASCO 2003; 22:1112.
9. Nemoto K, Ariga H, Kakuto Y, et al: Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol 2001; 61:165-168.
10. Yamashita H, Nakagawa K, Tago M, et al: Salvage radiotherapy for postoperative loco-regional recurrent esophageal cancer. Dis Esophagus 2005; 18:215-220.
11. Nishimura Y, Koike R, Nakamatsu K, et al: Concurrent chemoradiotherapy with protracted infusion of 5-FU and Cisplatin for postoperative recurrent or residual esophageal cancer. Jpn J Clin Oncol 2003; 33:341-345.
12. Nakajima Y, Nagai K, Kawano T, et al: Therapeutic strategy for postoperative liver metastasis from esophageal squamous cell carcinoma; clinical efficacy of and problem with hepatic arterial infusion chemotherapy. Hepatogastroenterology 2001; 48: 1652-1655.
13. Herskovic A, Martz K, al-Sarraf M, et al: Combined chemotherapy and radiotherapy cpmpared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593-1598.
14. Al-Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15:277-284.
15. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281:1623-1627.
16. Hilgenberg AD, Carey RW, Wilkinss EW, et al: Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 1988; 45:357-363.
17. Ajani JA, Ryan B, Rich TA, et al: Prolonged chemotherapy for localized squamous cell carcinoma of the esophagus. Eur J Cancer 1992; 28A:880-884.
18. Iizuka T, Kakegawa T, Ide H, et al: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992; 22:172-176.
19. Ohtsu A, Boku N, Muro K, et al: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17:2915-2921.
20. Nishimura Y, Suzuki M, Nakamatsu K, et al: Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 2002; 53:134-139.
21. Ishida K, Ando N, Yamamoto S, et al: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol 2004; 17:2915-2921.
22. Taguchi T, Wakui A, Nabeya K, et al: A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1992; 19:483-488. (In Japanese with English abstract)
23. Conroy T, Etienne PL, Adenis A, et al: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 1996; 14:164-170.
24. Lordick F, von Schilling C, Bernhard H, et al: Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003; 89:630-633.
25. Muro K, Hamaguchi T, Ohtsu A, et al: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15:955-999.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl cancer Inst 2000; 92:205-216.
27. National Cancer Institute: National Cancer Institute Common Toxicity Criteria v2.0. http://ctep.info.nih.gov/reporting/ctc.html (24 June 2007, data last accessed)
28. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83:288-291.
29. Sasaki Y, Amano T, Morita M, et al: Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 1991; 51:1472-1477.
30. Saito J, Sugawara S, Nakai Y, et al: Phase I/II study of combination chemotherapy with docetaxel and nedaplatin for unresectable non-small-cell lung cancer. Jpn J Lung Cancer 2000; 40:513. (In Japanese)